利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.033 秒)

    Agonists and antagonists of prolixin for the treatment of metabolic disorders
    1.
    发明授权
    Agonists and antagonists of prolixin for the treatment of metabolic disorders 失效
    激素和拮抗剂，用于治疗代谢紊乱

    公开(公告)号：US07344843B2

    公开(公告)日：2008-03-18

    申请号：US10496757

    申请日：2002-10-14

    申请人： John Lucas ,  Deno Dialynas ,  Kristen Briggs

    发明人： John Lucas ,  Deno Dialynas ,  Kristen Briggs

    IPC分类号： G01N33/53

    CPC分类号： G01N33/92 ,  A61K38/177 ,  G01N33/566 ,  G01N2333/70578 ,  G01N2500/00 ,  G01N2800/044

    摘要： The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of PROLIXIN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.

    摘要翻译： 本发明涉及代谢研究领域，特别涉及有效减少体重并可用于治疗与肥胖有关的疾病和病症的化合物的发现。 预期通过本发明的方法治疗的肥胖相关疾病或病症包括但不限于高脂血症，动脉粥样硬化，胰岛素抵抗，糖尿病和高血压。 特别地，本发明提供了鉴定和使用PROLIXIN活性的AGONISTS和ANTAGONISTS的方法，其中所述活性选自脂质分配，脂质代谢和胰岛素样活性。

    Xcrf polynucleotides and polypeptides and uses thereof
    2.
    发明申请
    Xcrf polynucleotides and polypeptides and uses thereof 审中-公开
    Xcrf多核苷酸和多肽及其用途

    公开(公告)号：US20060258567A1

    公开(公告)日：2006-11-16

    申请号：US10510002

    申请日：2003-03-26

    申请人： Kristen Briggs ,  Deno Dialynas ,  John Lucas ,  Aaron Scalia

    发明人： Kristen Briggs ,  Deno Dialynas ,  John Lucas ,  Aaron Scalia

    IPC分类号： A61K48/00 ,  A61K38/17

    CPC分类号： A61K48/00 ,  A61K9/0019 ,  A61K38/00 ,  C07K14/47

    摘要： The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. XCRF polypeptides have been identified that are beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.

    摘要翻译： 本发明涉及代谢研究领域。 代谢紊乱，如肥胖，是一个严重而广泛的公共卫生问题。 已经鉴定出有利于治疗代谢紊乱的XCRF多肽。 这些化合物应该有效减少体重和治疗与代谢有关的疾病和病症。 这些代谢相关的疾病和病症包括高脂血症，动脉粥样硬化，糖尿病和高血压。

    Agonists and antagonists of prolixin for the treatrment of metabolic disorders
    3.
    发明申请
    Agonists and antagonists of prolixin for the treatrment of metabolic disorders 失效
    激素和拮抗剂，用于治疗代谢紊乱

    公开(公告)号：US20050069971A1

    公开(公告)日：2005-03-31

    申请号：US10496757

    申请日：2002-10-14

    申请人： John Lucas ,  Deno Dialynas ,  Kristen Briggs

    发明人： John Lucas ,  Deno Dialynas ,  Kristen Briggs

    IPC分类号： A61K38/17 ,  A61P3/00 ,  C12Q1/26 ,  G01N33/566 ,  G01N33/92

    CPC分类号： G01N33/92 ,  A61K38/177 ,  G01N33/566 ,  G01N2333/70578 ,  G01N2500/00 ,  G01N2800/044

    摘要： The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of PROLIXIN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.

    摘要翻译： 本发明涉及代谢研究领域，特别涉及有效减少体重并可用于治疗与肥胖有关的疾病和病症的化合物的发现。 预期通过本发明的方法治疗的肥胖相关疾病或病症包括但不限于高脂血症，动脉粥样硬化，胰岛素抵抗，糖尿病和高血压。 特别地，本发明提供了鉴定和使用PROLIXIN活性的AGONISTS和ANTAGONISTS的方法，其中所述活性选自脂质分配，脂质代谢和胰岛素样活性。

    Genobix agonists and antagonists for use in the treatment of metabolic disorders
    4.
    发明申请
    Genobix agonists and antagonists for use in the treatment of metabolic disorders 审中-公开
    用于治疗代谢紊乱的Genobix激动剂和拮抗剂

    公开(公告)号：US20070129291A1

    公开(公告)日：2007-06-07

    申请号：US10480699

    申请日：2002-07-30

    申请人： John Lucas ,  Deno Dialynas ,  Kristen Briggs

    发明人： John Lucas ,  Deno Dialynas ,  Kristen Briggs

    IPC分类号： A61K38/22

    CPC分类号： A61K38/177 ,  A61K45/06 ,  G01N33/6863 ,  G01N2500/04 ,  G01N2500/10 ,  G01N2500/20

    摘要： The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of GENOBIX activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.

    摘要翻译： 本发明涉及代谢研究领域，特别涉及有效减少体重并可用于治疗与肥胖有关的疾病和病症的化合物的发现。 预期通过本发明的方法治疗的肥胖相关疾病或病症包括但不限于高脂血症，动脉粥样硬化，胰岛素抵抗，糖尿病和高血压。 特别地，本发明提供鉴定和使用GENOBIX活性的AGONISTS和ANTAGONISTS的方法，其中所述活性选自脂质分配，脂质代谢和胰岛素样活性。

    Agonists and antagonists of moxifin for the treatment of metabolic disorders
    5.
    发明申请
    Agonists and antagonists of moxifin for the treatment of metabolic disorders 审中-公开
    莫昔芬的激动剂和拮抗剂用于治疗代谢紊乱

    公开(公告)号：US20050054565A1

    公开(公告)日：2005-03-10

    申请号：US10485232

    申请日：2002-07-29

    申请人： John Lucas ,  Deno Dialynas ,  Kristen Briggs

    发明人： John Lucas ,  Deno Dialynas ,  Kristen Briggs

    IPC分类号： A61K38/00 ,  A61K38/17 ,  A61P3/00 ,  C07K14/705 ,  G01N33/68 ,  G01N33/53

    CPC分类号： A61K38/17 ,  A61K38/177 ,  C07K14/70578 ,  C07K2319/30 ,  G01N33/6863 ,  G01N33/6893 ,  G01N2333/70578 ,  G01N2500/04 ,  G01N2800/042

    摘要： The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of MOXIFIN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.

    摘要翻译： 本发明涉及代谢研究领域，特别涉及有效减少体重并可用于治疗与肥胖有关的疾病和病症的化合物的发现。 预期通过本发明的方法治疗的肥胖相关疾病或病症包括但不限于高脂血症，动脉粥样硬化，胰岛素抵抗，糖尿病和高血压。 特别地，本发明提供鉴定和使用MOXIFIN活性的AGONISTS和ANTAGONISTS的方法，其中所述活性选自脂质分配，脂质代谢和胰岛素样活性。

    Xobesin agonists and antagonists for the treatment of metabolic disorders
    6.
    发明申请
    Xobesin agonists and antagonists for the treatment of metabolic disorders 失效
    Xobesin激动剂和拮抗剂用于治疗代谢紊乱

    公开(公告)号：US20050003997A1

    公开(公告)日：2005-01-06

    申请号：US10485233

    申请日：2002-07-31

    申请人： John Lucas ,  Deno Dialynas ,  Kristen Briggs

    发明人： John Lucas ,  Deno Dialynas ,  Kristen Briggs

    IPC分类号： A61K38/17 ,  A61P3/00 ,  G01N33/68 ,  A61K31/00 ,  A61K38/00 ,  G01N33/53

    CPC分类号： G01N33/6863 ,  A61K38/177 ,  G01N2500/00 ,  G01N2500/04

    摘要： The present invention relates to the field of metabolic research, in particular the discovery of compounds effective for reducing body mass and useful for treating obesity-related diseases and disorders. The obesity-related diseases or disorders envisioned to be treated by the methods of the invention include, but are not limited to, hyperlipidemia, atherosclerosis, insulin resistance, diabetes, and hypertension. In particular, the invention provides for methods of identifying and using AGONISTS and ANTAGONISTS of XOBESIN activity, wherein said activity is selected from the group consisting of lipid partitioning, lipid metabolism, and insulin-like activity.

    摘要翻译： 本发明涉及代谢研究领域，特别涉及有效减少体重并可用于治疗与肥胖有关的疾病和病症的化合物的发现。 预期通过本发明的方法治疗的肥胖相关疾病或病症包括但不限于高脂血症，动脉粥样硬化，胰岛素抵抗，糖尿病和高血压。 特别地，本发明提供了鉴定和使用XOBESIN活性的AGONISTS和ANTAGONISTS的方法，其中所述活性选自脂质分配，脂质代谢和胰岛素样活性。

    Homotrimeric extended OBG3 globular head and uses thereof
    9.
    发明授权
    Homotrimeric extended OBG3 globular head and uses thereof 失效
    同源三聚体延伸OBG3球状头及其用途

    公开(公告)号：US07459433B2

    公开(公告)日：2008-12-02

    申请号：US10515033

    申请日：2003-05-26

    申请人： John Lucas ,  Jiunn-chern Yeh ,  Deno Dialynas

    发明人： John Lucas ,  Jiunn-chern Yeh ,  Deno Dialynas

    IPC分类号： C07K14/00 ,  A61K38/00

    CPC分类号： A61K38/17 ,  C07K14/5759

    摘要： The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, homotrimer of OBG3 polypeptide fragment comprising globular domain and all or part of OBG3 collagen-like region, has been identified that has utility for reducing body mass, for maintaining weight loss, and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.

    摘要翻译： 本发明涉及肥胖研究领域。 肥胖是一个严重而广泛的公共卫生问题。 已经鉴定了包含球状结构域和全部或部分OBG3胶原样区域的OBG3多肽片段的同三聚物，其具有用于减少体重，用于维持体重减轻和用于治疗肥胖相关疾病和病症的效用。 这些肥胖相关的疾病和病症包括高脂血症，动脉粥样硬化，糖尿病和高血压。

    Gmg-2 polynucleotides and polypeptides and uses thereof
    10.
    发明申请
    Gmg-2 polynucleotides and polypeptides and uses thereof 审中-公开
    Gmg-2多核苷酸和多肽及其用途

    公开(公告)号：US20060293225A1

    公开(公告)日：2006-12-28

    申请号：US10484707

    申请日：2002-07-25

    申请人： Deno Dialynas ,  John Lucas ,  Aaron Scalia ,  Hiroaki Tanaka

    发明人： Deno Dialynas ,  John Lucas ,  Aaron Scalia ,  Hiroaki Tanaka

    IPC分类号： A61K38/17

    CPC分类号： A61K38/1709 ,  C07K14/435 ,  C07K2319/00

    摘要： The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, homotrimer of GMG-2 polypeptide fragment comprising globular domain and all or part of GMG-2 collagen-like region, has been identified that has utility for reducing body mass, for maintaining weight loss, and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.

    摘要翻译： 本发明涉及肥胖研究领域。 肥胖是一个严重而广泛的公共卫生问题。 已经鉴定了包含球状结构域和全部或部分GMG-2胶原样区域的GMG-2多肽片段的同三聚物，其具有用于减少体重，用于维持体重减轻和用于治疗与肥胖有关的疾病和 疾病 这些肥胖相关的疾病和病症包括高脂血症，动脉粥样硬化，糖尿病和高血压。